Předmět: |
|
Zdroj: |
Obesity, Fitness & Wellness Week; 11/22/2024, p666-666, 1p |
Abstrakt: |
Researchers from Western University conducted a study on the inhibition of Elongation Factor 1a1 (EEF1A1) and its effects on liver health in a mouse model of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The study found that inhibiting EEF1A1 decreased liver steatosis, reduced lipid droplet size, and altered gene expression associated with various liver cell types. The research suggests that targeting EEF1A1 could be a potential therapeutic strategy for addressing MASLD progression. The study was published in AJP Gastrointestinal and Liver Physiology and was peer-reviewed. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|